Cencora is restructuring its entire distribution strategy to keep pace with the rapid growth of specialty pharmaceuticals and cold chain medicine demand.
Senior Vice President of Global Supply Chain Brent Wilhelm says the shift is being driven fundamentally by changes in the composition of the drug pipeline itself.
“70% of the new medicines being launched through this next year are in the specialty space,” Wilhelm said, underlining how dramatically the product mix has changed for major distributors.
More than half of those specialty medicines require cold chain handling, meaning packaging and storage capable of holding 2 to 8 degrees Celsius, or colder, throughout the entire transport window.
Meeting that standard at scale requires infrastructure investments that go well beyond what the pharmaceutical distribution industry has historically managed as routine.
Cencora has committed roughly $1 billion to supply chain investments over the past year, targeting the specialized handling and shipping capabilities that this new drug landscape demands.
A central pillar of that investment is a new centralized distribution site dedicated specifically to holding safety stock for critical inventories and high-priority medicines.
“So we have inventory closest to the customer to serve the day-to-day, but we hold back a certain amount of inventory centrally so that we can ship that product dynamically across the country based on demand,” Wilhelm explained.
That model reflects a deliberate balancing act, keeping stock positioned near customers for routine fulfilment while maintaining flexible centralized reserves for shifting demand patterns.
Reimbursement pressure is adding another layer of complexity, pushing distributors to pursue AI-driven flexibility alongside their physical infrastructure upgrades.
The dual approach, local inventory proximity combined with centrally managed safety stock, is designed to handle the volatility that specialty and cold chain volumes tend to introduce into supply chains.
Wilhelm’s comments suggest that traditional distribution models, built around high-volume, ambient-temperature products, are increasingly ill-suited to where pharmaceutical growth is heading.
The scale of cold chain demand is particularly striking, given that temperature-sensitive handling was once considered a niche requirement rather than a mainstream distribution challenge.
With specialty drugs now dominating new product launches, distributors like Cencora are under sustained pressure to rethink infrastructure, staffing, and logistics technology at the same time.
The $1 billion investment signals that Cencora views this transformation not as a short-term adjustment but as a foundational shift in how pharmaceutical supply chains must operate going forward.